266 Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC)

• Weimin Li,
• Ross Stewart,
• Thomas Powles,
• Joaquim Bellmunt,
• Feng Xiao,
• Ashok Gupta,
• Jill Walker,
• Melissa de los Reyes,
• Matthew Galsky,
• Sophie Wildsmith,
• Anne L’Hernault,
• Hannah Bye,
• Philip He,
• Qu Zhang,
• Rajiv Raja,
• Wendy Levin,
• Alexandra Drakaki,
• Michiel van der Heijden

Affiliations

Weimin Li

1AstraZeneca, Cambridge, UK

Ross Stewart

Aff3 grid.417815.e0000000104335842MedImmune Cambridge United Kingdom

Thomas Powles

Aff3 grid.4868.20000000121711133Barts Cancer InstituteQueen Mary University of London London UK

Joaquim Bellmunt

Aff399 grid.65499.370000000121069910Dana-Farber Cancer Institute, Harvard Medical School Boston MA USA

Feng Xiao

Aff2 grid.418152.bMedImmune Gaithersburg MD USA

Ashok Gupta

Aff2 grid.418152.bMedImmune Gaithersburg MD USA

Jill Walker

AstrZeneca, Gaithersburg, MD, USA

Melissa de los Reyes

Astrazeneca, Gaithersburg, MD, USA

Matthew Galsky

1Icahn School of Medicine at Mount Sinai, New York, NY, USA

Sophie Wildsmith

1AstraZeneca, Cambridge, UK

Anne L’Hernault

1AstraZeneca, Cambridge, UK

Hannah Bye

1AstraZeneca, Cambridge, UK

Philip He

1AstraZeneca, Cambridge, UK

Qu Zhang

1AstraZeneca, Cambridge, UK

Rajiv Raja

1AstraZeneca, Cambridge, UK

Wendy Levin

1AstraZeneca, Cambridge, UK

Alexandra Drakaki

5University of California, Los Angeles, CA, USA

Michiel van der Heijden

6Netherlands Cancer Institute, Amsterdam, 1066 CX, Netherlands